Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENXGet Rating) in a report released on Sunday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Stock Performance

Shares of Tenax Therapeutics stock opened at $0.09 on Friday. The company has a fifty day simple moving average of $0.17 and a 200-day simple moving average of $0.34. Tenax Therapeutics has a 12-month low of $0.08 and a 12-month high of $1.46.

Tenax Therapeutics (NASDAQ:TENXGet Rating) last issued its earnings results on Thursday, August 11th. The specialty pharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Equities research analysts forecast that Tenax Therapeutics will post -0.42 earnings per share for the current year.

About Tenax Therapeutics

(Get Rating)

Tenax Therapeutics, Inc, a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension.

Featured Stories

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.